• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    President & CEO Maraoui Claude sold $360,762 worth of shares (70,556 units at $5.11), decreasing direct ownership by 3% to 2,092,874 units (SEC Form 4)

    3/5/25 7:53:31 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DERM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Maraoui Claude

    (Last) (First) (Middle)
    C/O JOURNEY MEDICAL CORPORATION
    9237 E VIA DE VENTURA BLVD., SUITE 105

    (Street)
    SCOTTSDALE AZ 85258

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Journey Medical Corp [ DERM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President & CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, $0.0001 par value 03/03/2025 S 23,508(1) D $5.19(2) 2,139,922(3) D
    Common Stock, $0.0001 par value 03/04/2025 S 28,901(4) D $5.04(5) 2,111,021(3) D
    Common Stock, $0.0001 par value 03/05/2025 S 18,147(6) D $5.13(7) 2,092,874(3) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. In connection with the vesting of restricted stock units which vested as of various dates, a total of 23,508 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units.
    2. Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 3, 2025, was $5.00 to $5.57. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price.
    3. Includes restricted stock units, which vest over various time periods.
    4. In connection with the vesting of restricted stock units which vested as of various dates, a total of 28,901 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units.
    5. Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 4, 2025, was $5.00 to $5.17. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price.
    6. In connection with the vesting of restricted stock units which vested as of various dates, a total of 18,147 of such underlying shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock units.
    7. Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on March 5, 2025, was $5.02 to $5.26. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price.
    /s/ Ramsey Alloush, attorney-in-fact 03/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DERM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DERM

    DatePrice TargetRatingAnalyst
    8/22/2024$9.00Buy
    Rodman & Renshaw
    6/28/2024$11.00Buy
    ROTH MKM
    2/25/2022$9.00Overweight
    Cantor Fitzgerald
    12/16/2021$15.00Buy
    Roth Capital
    12/7/2021$14.00Buy
    B. Riley Securities
    More analyst ratings

    $DERM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

      Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint's lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma FDA accepted New Drug Application filing for priority review for CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and adva

      3/31/25 4:05:13 PM ET
      $CKPT
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Leadership Updates

    Live Leadership Updates

    See more
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

      SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

      7/11/24 4:05:39 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

      SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. Claude Maraoui, Co-Founder, President and Chief

      5/1/24 4:01:30 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Journey Medical with a new price target

      Rodman & Renshaw initiated coverage of Journey Medical with a rating of Buy and set a new price target of $9.00

      8/22/24 7:21:37 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM resumed coverage on Journey Medical with a new price target

      ROTH MKM resumed coverage of Journey Medical with a rating of Buy and set a new price target of $11.00

      6/28/24 7:38:15 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Journey Medical with a new price target

      Cantor Fitzgerald initiated coverage of Journey Medical with a rating of Overweight and set a new price target of $9.00

      2/25/22 9:05:17 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rosenwald Lindsay A Md bought $30,400 worth of shares (10,000 units at $3.04), increasing direct ownership by 7% to 144,245 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/27/24 7:00:16 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maraoui Claude bought $34,790 worth of shares (10,000 units at $3.48), increasing direct ownership by 0.46% to 2,163,430 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/25/24 4:03:29 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smith Justin Adam bought $104,100 worth of shares (30,000 units at $3.47), increasing direct ownership by 29% to 134,717 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/25/24 4:02:02 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Maraoui Claude sold $33,065 worth of shares (4,834 units at $6.84), decreasing direct ownership by 0.21% to 2,348,313 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:34:52 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Benesch Joseph sold $16,478 worth of shares (2,409 units at $6.84), decreasing direct ownership by 1% to 203,557 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:34:22 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO Alloush Ramsey sold $19,542 worth of shares (2,857 units at $6.84), decreasing direct ownership by 0.56% to 504,817 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:31:11 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Financials

    Live finance-specific insights

    See more
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

      FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 26, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approve

      3/26/25 4:01:00 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

      SCOTTSDALE, Ariz., March 19, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2024 financial results after the U.S. financial markets close on Wednesday, March 26, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 26, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S.

      3/19/25 4:01:56 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Journey Medical Corporation

      DEFA14A - Journey Medical Corp (0001867066) (Filer)

      4/29/25 4:07:56 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Journey Medical Corporation

      DEF 14A - Journey Medical Corp (0001867066) (Filer)

      4/29/25 4:06:47 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Journey Medical Corporation

      PRE 14A - Journey Medical Corp (0001867066) (Filer)

      4/18/25 4:01:23 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      11/29/24 2:00:25 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Journey Medical Corporation (Amendment)

      SC 13G/A - Journey Medical Corp (0001867066) (Subject)

      12/29/22 5:15:07 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      8/17/22 4:01:13 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care